Revenue grew 13% year-over-year to $6,768m, with underlying EBITDA up 3.2% to $300m and NPAT at $125m. FY26 EBITDA guidance is reaffirmed, capex to fall in FY27, and strong growth is expected across Healthcare and Animal Care segments, supported by acquisitions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.